106 related articles for article (PubMed ID: 27344734)
1. [Antisese oligonucleotide therapy for patients with castration-resistant prostate cancer].
Muramaki M; Miyake H; Fujisawa M
Nihon Rinsho; 2016 May; 74 Suppl 3():234-7. PubMed ID: 27344734
[No Abstract] [Full Text] [Related]
2. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
Miyake H; Fujisawa M
Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
[TBL] [Abstract][Full Text] [Related]
3. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
Miyake H; Hara I; Fujisawa M; Gleave ME
Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
[TBL] [Abstract][Full Text] [Related]
4. Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.
Stein CA
Clin Genitourin Cancer; 2015 Oct; 13(5):407-9. PubMed ID: 26119230
[No Abstract] [Full Text] [Related]
5. Second-generation antisense drug for prostate cancer.
Kerr C
Lancet Oncol; 2004 Nov; 5(11):646. PubMed ID: 15536686
[No Abstract] [Full Text] [Related]
6. PARP inhibition in castration-resistant prostate cancer.
Nappi L; Gleave ME
Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
[No Abstract] [Full Text] [Related]
7. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
Zielinski R; Chi KN
Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
[TBL] [Abstract][Full Text] [Related]
8. Stratifying prostate patients for olaparib.
Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
[TBL] [Abstract][Full Text] [Related]
9. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review).
Magadoux L; Isambert N; Plenchette S; Jeannin JF; Laurens V
Int J Oncol; 2014 Sep; 45(3):919-28. PubMed ID: 24969394
[TBL] [Abstract][Full Text] [Related]
10. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.
Xiu P; Dong XF; Li XP; Li J
World J Gastroenterol; 2015 Jul; 21(27):8262-70. PubMed ID: 26217078
[TBL] [Abstract][Full Text] [Related]
11. Drug therapies for metastatic castration-resistant prostate cancer.
El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
[TBL] [Abstract][Full Text] [Related]
12. [Docetaxel and prostate cancer: Early but not too early].
Penel N; Ryckewaert T; Amela EY
Bull Cancer; 2015 Sep; 102(9):710-2. PubMed ID: 26235414
[No Abstract] [Full Text] [Related]
13. Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer.
Karaki S; Benizri S; Mejías R; Baylot V; Branger N; Nguyen T; Vialet B; Oumzil K; Barthélémy P; Rocchi P
J Control Release; 2017 Jul; 258():1-9. PubMed ID: 28472637
[TBL] [Abstract][Full Text] [Related]
14. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
15. [Short-term neoadjuvant hormone therapy enhanced expression of clusterin in prostate cancer].
Niu YN; Xin DQ; He ZS; Zhou LQ; Pan BN; Na YQ; Guo YL
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):394-7. PubMed ID: 15854351
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
Pinto A
Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
[TBL] [Abstract][Full Text] [Related]
17. [Treatment sequence using newly developed agents for men with castration resistant prostate cancer].
Fujimoto N
Nihon Rinsho; 2014 Dec; 72(12):2193-7. PubMed ID: 25518357
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.
Wiechno P; Somer BG; Mellado B; Chłosta PL; Cervera Grau JM; Castellano D; Reuter C; Stöckle M; Kamradt J; Pikiel J; Durán I; Wedel S; Callies S; André V; Hurt K; Brown J; Lahn M; Heinrich B
Eur Urol; 2014 Mar; 65(3):516-20. PubMed ID: 24246407
[TBL] [Abstract][Full Text] [Related]
19. [Sequential therapy for castration-resistant prostate cancer].
Nozawa M; Uemura H
Nihon Rinsho; 2016 May; 74 Suppl 3():644-8. PubMed ID: 27344809
[No Abstract] [Full Text] [Related]
20. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
